U.S. Centers for Disease Control Guidance Includes EUROIMMUN Assay in its Two-Step Testing Algorithm for Dengue Virus

Author's Avatar
Feb 03, 2022

EUROIMMUN, a PerkinElmer, Inc. (NYSE:PKI, Financial) company, today announced that its EUROIMMUN%26reg%3B+Anti-Dengue+Virus+NS1+Type+1-4+ELISA+%28IgG%29 (research use only) was cited by the U.S. Centers for Disease Control and Prevention (CDC) as part of the two-step+testing+algorithm guidance for pre-vaccination screening for the Dengvaxia® vaccine that is used to prevent future dengue disease. According to the CDC MMWR publication, the Dengvaxia vaccine will be available this year for children and adolescents between the ages of 9 and 16 who have laboratory-confirmed previous dengue virus infection and are living in an area where dengue is endemic.